Instrument Inactif

Autres langues ASKA Pharmaceutical Co., Ltd. Japan Exchange

Actions

4514

JP3541200006

Produits pharmaceutiques

Autres langues

04/09	Metagen Therapeutics, Inc. announced that it has received ¥3.71 billion in funding from a group of investors
04/08	ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2026
25/06	Declaration of Voting Results by Asuka Pharmaceutical
27/05	Dalton Investment strongly oppose conditional activation of countermeasures announced by ASKA Pharmaceutical Holdings on May 25
25/05	Aska pharmaceutical - plan to put to shareholders proposal on countermeasures against potential large-scale share purchase by Dalton and related parties
11/05	Asuka Pharmaceutical Opposes Nippon Active Value Fund Plc?s Shareholder Proposal for Board Changes at 2026 Annual Meeting
11/05	ASKA Pharmaceutical Holdings Co.,Ltd. Announces Change in Dividend Policy
11/05	ASKA Pharmaceutical Holdings Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027
11/05	ASKA Pharmaceutical Holdings Co.,Ltd. Proposes Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 25, 2026; Provides Dividend Guidance for End of Second Quarter of Fiscal Year Ending March 31, 2027
11/05	ASKA Pharmaceutical Holdings Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2027
11/05	ASKA Pharmaceutical Holdings Co.,Ltd. Announces Retirement of Kazuhiro Chiku as Audit & Supervisory Board Member, Effective June 24, 2026
14/04	FTS AMBROSE HOLDINGS, INC. announced that it has received funding from ASKA Pharmaceutical Holdings Co.,Ltd.
24/03	Insilico Medicine And ASKA Pharmaceutical Enter Strategic Research Collaboration For Women's Health
24/03	Aska Pharmaceutical Holdings Co Ltd - Insilico Medicine and Aska Pharmaceutical expand partnership to discover novel targets for women's health
23/03	ASKA Targets 85 Billion Yen Revenue Under New Mid-term Plan
02/02	ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2025
31/12	Metagen Therapeutics, Inc. amended terms of the transaction
04/11	ASKA Pharmaceutical Holdings Co.,Ltd. Announces Dividend for the Second Quarter of Year Ending March 31, 2026, Payable on November 28, 2025
04/11	ASKA Pharmaceutical Holdings Co.,Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026
20/10/25	ASKA Pharmaceutical Co., Ltd. and Daiichi Sankyo Healthcare Co., Ltd. Jointly Announce the Marketing Authorization and Distribution as a Switch to OTC Use of the Emergency Contraceptive Pill "NORLEVO®?
14/10/25	Japanese Shares Slip as Coalition Rift Clouds Takaichi's Path to Premiership
14/10/25	ASKA Pharmaceutical Extends Anti-Takeover Measures Amid Dalton Buyout Concerns
30/09/25	Aska Pharmaceutical: Dalton notified us it is withdrawing plan for large-scale purchase of Aska shares
16/09/25	Aska Pharmaceutical Holdings: Will convey concerns to Dalton, urge to fulfill obligation to 'proactively' provide information in accordance with guidelines and response policy
08/09/25	Metagen Therapeutics, Inc. announced that it expects to receive ¥2.33 billion in funding from a group of investors